PMID- 27789989
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240326
IS  - 1179-156X (Print)
IS  - 1179-156X (Electronic)
IS  - 1179-156X (Linking)
VI  - 1
DP  - 2009
TI  - Bioboosters in the treatment of rheumatic diseases: a comprehensive review of 
      currently available biologics in patients with rheumatoid arthritis, ankylosing 
      spondylitis and psoriatic arthritis.
PG  - 163-178
AB  - Immunologic research has clarified many aspects of the pathogenesis of 
      inflammatory rheumatic disorders. Biologic drugs acting on different steps of the 
      immune response, including cytokines, B- and T-cell lymphocytes, have been 
      marketed over the past 10 years for the treatment of rheumatoid arthritis (RA), 
      ankylosing spondylitis (AS), and psoriatic arthritis (PsA). Randomized controlled 
      trials (RCTs) of anti-cytokine agents in RA (including the anti-tumor necrosis 
      factor alpha (TNFalpha) drugs infliximab, etanercept, adalimumab, golimumab, 
      certolizumab, anti-interleukin (IL)-1 anakinra, and anti-IL-6 tocilizumab) 
      demonstrated a significant efficacy compared to traditional therapies, if 
      combined with methotrexate (MTX), as measured by ACR 20, 50 and 70 response 
      criteria. The new therapies have also been demonstrated to be superior to MTX in 
      slowing or halting articular damage. RCTs have shown the efficacy of anti-TNFalpha in 
      AS patients through significant improvement of symptoms and function. Trials of 
      anti-TNFalpha in PsA patients showed marked improvement of articular symptoms for 
      psoriasis and radiological disease progression. More recent studies have 
      demonstrated the efficacy of B-cell depletion with rituximab, and T-cell 
      inactivation with abatacept. All these drugs have a satisfactory safety profile. 
      This paper reviews the different aspects of efficacy and tolerability of 
      biologics in the therapy of RA, AS, and PsA.
FAU - Cantini, Fabrizio
AU  - Cantini F
AD  - Second Division of Medicine, Rheumatology Unit, Hospital of Prato, Italy.
FAU - Nannini, Carlotta
AU  - Nannini C
AD  - Second Division of Medicine, Rheumatology Unit, Hospital of Prato, Italy.
FAU - Niccoli, Laura
AU  - Niccoli L
AD  - Second Division of Medicine, Rheumatology Unit, Hospital of Prato, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20091204
PL  - New Zealand
TA  - Open Access Rheumatol
JT  - Open access rheumatology : research and reviews
JID - 101688698
PMC - PMC5074719
OTO - NOTNLM
OT  - abatacept
OT  - ankylosing spondylitis
OT  - anti-TNF
OT  - anti-cytokine agents
OT  - psoriatic arthritis
OT  - rheumatoid arthritis
OT  - rituximab
COIS- The authors disclose no conflicts of interest.
EDAT- 2009/12/04 00:00
MHDA- 2009/12/04 00:01
PMCR- 2009/12/04
CRDT- 2009/12/04 00:00
PHST- 2009/12/04 00:00 [pubmed]
PHST- 2009/12/04 00:01 [medline]
PHST- 2009/12/04 00:00 [entrez]
PHST- 2009/12/04 00:00 [pmc-release]
AID - oarrr-1-163 [pii]
AID - 10.2147/oarrr.s4490 [doi]
PST - epublish
SO  - Open Access Rheumatol. 2009 Dec 4;1:163-178. doi: 10.2147/oarrr.s4490. 
      eCollection 2009.